How to buy Fulgent Genetics stock

Fulgent Genetics, Inc is a diagnostics & research business based in the US. Fulgent Genetics shares (FLGT) are listed on the NASDAQ and all prices are listed in US Dollars. Fulgent Genetics employs 480 staff and has a trailing 12-month revenue of around 0.00.

Fulgent Genetics share price

Use our graph to track the performance of FLGT stocks over time.

Fulgent Genetics shares at a glance

• Key figures

Information last updated 2021-04-30.

52-week range	$12.36 - $189.89
50-day moving average	$94.88
200-day moving average	$75.49
Wall St. target price	$89.00
PE ratio	8.9327
Dividend yield	N/A (0%)
Earnings per share (TTM)	$8.91

Buy Fulgent Genetics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Fulgent Genetics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Fulgent Genetics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Fulgent Genetics under- or over-valued?

Valuing Fulgent Genetics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Fulgent Genetics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Fulgent Genetics's P/E ratio

Fulgent Genetics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 9x. In other words, Fulgent Genetics shares trade at around 9x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Fulgent Genetics's PEG ratio

Fulgent Genetics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.32. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Fulgent Genetics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Fulgent Genetics's EBITDA

Fulgent Genetics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $298.4 million.

The EBITDA is a measure of a Fulgent Genetics's overall financial performance and is widely used to measure a its profitability.

Fulgent Genetics financials

Revenue TTM	$421.7 million
Operating margin TTM	70.05%
Gross profit TTM	$331.9 million
Return on assets TTM	46.79%
Return on equity TTM	65.72%
Profit margin	50.82%
Book value	$20.21
Market capitalisation	$2.3 billion

TTM: trailing 12 months

Shorting Fulgent Genetics shares

There are currently 6.1 million Fulgent Genetics shares held short by investors – that's known as Fulgent Genetics's "short interest". This figure is 5.8% up from 5.8 million last month.

There are a few different ways that this level of interest in shorting Fulgent Genetics shares can be evaluated.

Fulgent Genetics's "short interest ratio" (SIR)

Fulgent Genetics's "short interest ratio" (SIR) is the quantity of Fulgent Genetics shares currently shorted divided by the average quantity of Fulgent Genetics shares traded daily (recently around 1.5 million). Fulgent Genetics's SIR currently stands at 4.05. In other words for every 100,000 Fulgent Genetics shares traded daily on the market, roughly 4050 shares are currently held short.

However Fulgent Genetics's short interest can also be evaluated against the total number of Fulgent Genetics shares, or, against the total number of tradable Fulgent Genetics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Fulgent Genetics's short interest could be expressed as 0.21% of the outstanding shares (for every 100,000 Fulgent Genetics shares in existence, roughly 210 shares are currently held short) or 0.3036% of the tradable shares (for every 100,000 tradable Fulgent Genetics shares, roughly 304 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Fulgent Genetics.

Find out more about how you can short Fulgent Genetics stock.

Fulgent Genetics share dividends

We're not expecting Fulgent Genetics to pay a dividend over the next 12 months.

Fulgent Genetics share price volatility

Over the last 12 months, Fulgent Genetics's shares have ranged in value from as little as $12.36 up to $189.89. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Fulgent Genetics's is 1.6214. This would suggest that Fulgent Genetics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Fulgent Genetics overview

Fulgent Genetics, Inc. , together with its subsidiaries, provides COVID-19 testing and genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. The company primarily serves insurance, hospitals, and medical institutions. It sells its tests through internal sales force, as well as through independent sales representatives in the United States and internationally. Fulgent Genetics has collaboration with PWNHealth to provide at-home COVID-19 test capabilities. The company was formerly known as Fulgent Diagnostics, Inc.

Frequently asked questions

• What percentage of Fulgent Genetics is owned by insiders or institutions?

  Currently 34.224% of Fulgent Genetics shares are held by insiders and 33.911% by institutions.

• How many people work for Fulgent Genetics?

  Latest data suggests 480 work at Fulgent Genetics.

• When does the fiscal year end for Fulgent Genetics?

  Fulgent Genetics's fiscal year ends in December.

• Where is Fulgent Genetics based?

  Fulgent Genetics's address is: 4978 Santa Anita Avenue, Temple City, CA, United States, 91780

• What is Fulgent Genetics's ISIN number?

  Fulgent Genetics's international securities identification number is: US3596641098

• What is Fulgent Genetics's CUSIP number?

  Fulgent Genetics's Committee on Uniform Securities Identification Procedures number is: 359664109